Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vor Biopharma Inc.

NASDAQ: VOR · Life Sciences · 2 alerts · CIK 1817229

Share price
$18.97Close, Nov 16
Market cap
$1.17B
Shares outstanding
61.43MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vor Biopharma Inc. filings on SEC EDGAR ↗

7:31 AM ET 8-K
Licensing Deal

Vor Biopharma Licensing Deal with RemeGen Co., Ltd. Worth $10M

Vor Biopharma expanded its existing partnership with RemeGen by entering into an amended and restated license agreement to add RC298, a next-generation dual BAFF/APRIL inhibitor, to its exclusive development and commercialization rights outside of Greater China. Vor Bio will pay an upfront cash payment of $10 million and issue a pre-funded warrant for 2.3 million shares, with RemeGen eligible for up to $630 million in development and regulatory milestones plus tiered royalties.

Value
$10M
Counterparty
RemeGen Co., Ltd.
8:01 AM ET 10-Q
Financial Results

Vor Biopharma Q3 2026 Results: Net Loss of $86.7M, Loss Narrows

Vor Biopharma Inc. is a clinical-stage biotechnology company that remains pre-revenue, incurring significant net losses since inception. The company is focused on the development of its lead product candidate, telitacicept, and expects to require substantial additional funding to support ongoing research and clinical trials.

Key figure
Net loss $86.7M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.